^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Esophageal Adenocarcinoma |
| Drug: | eprenetapopt (APR-246) (p53 reactivator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma
Excerpt:
APR-246 upregulated p53 target genes, inhibited clonogenic survival and induced cell cycle arrest as well as apoptosis in OAC cells harbouring p53 mutations. Sensitivity to APR-246 correlated with cellular levels of mutant p53 protein.
DOI:
10.1136/gutjnl-2015-309770
